Clinical Trials Directory

Trials / Completed

CompletedNCT00569049

Molecular Analysis of Breast Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
788 (actual)
Sponsor
Stanford University · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

This is a research-based study that is looking at the biologic features of breast tissue, lymph node tissue, or blood in order to study breast cancer development growth, and spread. Through tissue and/or blood samples we hope to gain further knowledge and understanding of how to improve diagnosis and treatment of breast cancer by identifying the molecular markers that predict clinical outcome and response to therapy.

Detailed description

The tissue obtained in this protocol will be used for genome-wide examination of DNA, RNA expression profiling, proteomic analyses, isolation and analyses of normal and cancer stem cells, isolation and analyses of circulating tumor cells, possible analyses of immune cells, and possible analyses of serum factors. The tissue may also be used to develop patient-specific cell culture models or mouse xenograft models of breast cancer for biologic study of tumor progression and metastases and for therapeutic testing. In general, the tissue will be used in studies that will molecularly classify tumors, identify prognostic markers, identify potential therapeutic markers, identify potential treatment targets, and help us better understand the biology and specific role played by different tumor cells in the metastatic process. The ultimate goal is to use molecular analyses to improve the diagnosis and treatment of breast cancer.

Conditions

Interventions

TypeNameDescription
PROCEDUREbreast tissue, lymph node tissue or bloodMolecular Analyses of samples

Timeline

Start date
1996-05-01
Primary completion
2011-07-01
Completion
2011-07-01
First posted
2007-12-06
Last updated
2025-02-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00569049. Inclusion in this directory is not an endorsement.